Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-05-07Clinical Trial Update: Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell [Phase 1]
Phase 1 study updating on CAR-20/19-T cells in relapsed/refractory B-cell lymphomas; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating bortezomib, rituximab, dexamethasone with or without temsirolimus in untreated or relapsed Waldenström macroglobu…
-
FDA approval · 2021-04-30FDA Approved: CARMUSTINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for Carmustine submitted by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. This actio…
-
CLINICAL_TRIALS trial_result · 2021-03-11Clinical Trial Update: Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial update assessing rituximab with combination chemotherapy for non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating bendamustine as a bridge to autologous or allogeneic transplant for relapsed/refractory lymphoma has completed wi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma [Phase 2]
Phase II trial evaluating meloxicam plus filgrastim in patients with multiple myeloma and non-Hodgkin's lymphoma has completed with results …
-
CLINICAL_TRIALS trial_result · 2021-02-15Clinical Trial Update: Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating combination chemotherapy with or without rituximab in relapsed non-Hodgkin's lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial comparing chemoradiotherapy and peripheral stem cell transplantation versus combination chemotherapy in non-Hodgkin's lymphoma…
-
CLINICAL_TRIALS trial_result · 2021-01-28Clinical Trial Update: Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL [Phase 1]
Phase 1 study evaluating tirabrutinib as monotherapy in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia has comple…
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. [Phase 1]
Phase I dose-escalation study of efavirenz in solid tumors and non-Hodgkin lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: Stem Cell Transplant for Hematological Malignancy [NA]
Clinical trial update on stem cell transplantation for hematologic malignancies; status terminated with results posted in 2021.
-
FDA approval · 2021-01-14FDA Approved: VINCRISTINE SULFATE — Supplemental Application (Hospira, Inc.)
The FDA approved a supplemental application filed by Hospira for vincristine sulfate, a generic vincristine product.
-
CLINICAL_TRIALS trial_result · 2020-12-19Clinical Trial Update: Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial update for antineoplaston therapy in non-Hodgkin lymphoma; study is terminated with results posted.
-
FDA approval · 2020-12-17FDA Approved: RIABNI — Original Application (Amgen, Inc)
FDA approved RIABNI (rituximab-arrx) from Amgen as a biosimilar to rituximab via Original Application.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating HCD122 in adults with Non-Hodgkin's or Hodgkin's lymphoma following at least two prior therapies has b…
-
CLINICAL_TRIALS trial_result · 2020-11-13Clinical Trial Update: Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical study evaluating CAR-T cells targeting CD19 and CD22 for relapsed or refractory B cell non-Hodgkin lymphoma; status not provided.
-
CLINICAL_TRIALS trial_result · 2020-11-03Clinical Trial Update: T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies [Phase 1, Phase 2]
A clinical trial update for T-cells expressing anti-CD19 CAR in pediatric and young adult patients with B-cell malignancies across Phase 1 a…
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: A Study for Patients With Non-Hodgkin's Lymphomas [Phase 2]
Phase 2 trial update for a study in non-Hodgkin's lymphomas has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-10-05Clinical Trial Update: Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas [Phase 2]
Phase IIa trial evaluating redirected autologous T cells engineered with anti-CD19 attached to TCRz and 4-signaling domains in CD19+ B-cell …
-
CLINICAL_TRIALS withdrawal · 2020-10-05Clinical Trial Update: Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL [Phase 3]
A Phase 3 trial comparing fludarabine, pixantrone, and rituximab versus fludarabine and rituximab for relapsed or refractory indolent non-Ho…
-
CLINICAL_TRIALS trial_result · 2020-09-10Clinical Trial Update: Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases [Phase 2]
Phase 2 trial evaluating myeloablative umbilical cord blood transplantation in various hematological diseases has completed with results pos…
-
CLINICAL_TRIALS trial_result · 2020-08-31Clinical Trial Update: Zevalin-beam for Aggressive Lymphoma [Phase 3]
Phase 3 trial update for Zevalin-beam in aggressive non-Hodgkin's lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-31Clinical Trial Update: Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma [Phase 1]
Phase 1 trial of anti-CD19 white blood cells in children and young adults with B-cell leukemia or lymphoma completed; results posted in 2020…
-
CLINICAL_TRIALS trial_result · 2020-08-18Clinical Trial Update: Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab [Phase 3]
Phase 3 trial comparing ABP798 to rituximab in non-Hodgkin lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-14Clinical Trial Update: Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma [Phase 1, Phase 2]
A phase 1/2 trial evaluating pembrolizumab plus lenalidomide in relapsed Hodgkin and non-Hodgkin lymphoma was terminated with results posted…